Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon
CardiacSense, an Israel-based healthcare technology company, gained FDA clearance for its CSF-3 medical watch

Regulatory Roundup: FDA clears new medical watch, considers empagliflozin for CKD and much more

Our monthly review of FDA-related news items in the world of cardiology includes updates from CardiacSense, MedAlliance, Lupin, Realize Medical and Eli Lilly and Company. 

FDA announces new IABP recall after 4 serious injuries, 1 death

The new recall includes nearly 4,500 devices. There have been 134 incidents so far, including 5 adverse events.  

An example if an implantable cardioverter defibrillator (ICD and its leads connected to the heart. As the leads or deveice wears out, there are recommendations to remove the leads and put in new ones. Image courtesy of RSNA

Infection, heart failure the most common reasons for early mortality after transvenous lead removal

Early mortality specifically related to complications during the TLR procedure was quite rare. 

Thumbnail

Medicare update designed to help heart failure patients may have the opposite effect

When Medicare made it easier for heart failure patients to receive a LVAD at a hospital that does not perform heart transplants, the change was intended to improve patient access. It turns out, however, that the policy shift could be linked to an unintended consequence. 

hospital ward

Why cardiologists should pay close attention to rehospitalizations after TAVR or SAVR

A new analysis in Circulation: Cardiovascular Interventions examined rehospitalization rates after AVR, noting that they are consistently associated with worse outcomes and a higher risk of patient mortality.

The Dexcom G7 Continuous Glucose Monitoring System

Regulatory Roundup: FDA news on omecamtiv mecarbil for HFrEF, 'world's smallest heart pump' and more

Read our monthly recap of some of the biggest FDA-related stories that have hit cardiology, including updates related to Cytokinetics, Dexcom and Abiomed. 

Thumbnail

AI specialists ink deal with Pfizer to target cardiac amyloidosis

Cardiac amyloidosis can be especially challenging to identify and diagnose, making it a perfect target for advanced AI models.

New discovery could reduce the risk of heart damage among cancer patients

Researchers have identified new details about the link between certain cancer therapies and heart complications. Could their work lead to key improvements in patient care?

Displaying 185 - 192 of 1270

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.